The pharmaceutical industry is no stranger to challenges and setbacks, especially in the area of neurological and psychiatric treatments. AbbVie, a multinational biopharmaceutical company, recently faced a significant hurdle when its promising schizophrenia drug, emraclidine, failed to meet
The recent approval of Aucatzyl by the FDA marks a significant advancement in the treatment landscape for patients with B-cell precursor acute lymphoblastic leukemia, especially those whose disease has progressed following initial chemotherapy treatments. Developed by U.K.-based Autolus
The election of Donald Trump and his return to the White House have sparked significant discussions about the potential impacts on various sectors, particularly the biopharma and vaccine industries. With anticipated shifts in federal policies and key personnel appointments, stakeholders are keenly
Thermo Fisher Scientific is making significant strides in the Indian biopharma market with the announcement of a new bioprocess design center (BDC) in Genome Valley, Hyderabad. This 10,000 square-foot facility, expected to open early next year, is part of a broader initiative by the company to
Fujifilm Diosynth Biotechnologies, a leading CDMO in the field of biologics, vaccines, advanced therapies, and oncolytic viruses, has embarked on the initial phase of a massive expansion project at their facility in Hillerød, Denmark. By adding six mammalian cell bioreactors to the existing
October 2024 saw a surge in biotech investments, with notable contributions from companies across North America, Europe, and the Asia-Pacific regions. Major players like Treeline Biosciences, Kailera Therapeutics, and Seaport Therapeutics secured substantial funding, reflecting the growing
